

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



國藥控股股份有限公司

SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PROPOSED CHANGE OF NON-EXECUTIVE DIRECTOR

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Sinopharm Group Co. Ltd. (the “**Company**”) hereby announces that on 9 June 2025, due to the work arrangement, Mr. Hu Ligang (“**Mr. Hu**”) tendered his resignation as a non-executive Director to the Board. The above resignation shall take immediate effect. On the same day, the Board resolved to propose to appoint Mr. Hu as a vice president of the Company. The above appointment shall take immediate effect and the term of office shall expire on 14 September 2026.

Mr. Hu confirmed that he has no disagreement with the Board and there is no other matter relating to his resignation that needs to be brought to the attention of the shareholders (the “**Shareholders**”) and creditors of the Company.

During the term of office, Mr. Hu diligently and faithfully performed his duties. The Board would like to take this opportunity to express its sincere gratitude to his contribution to the strategic development and the work of the Board of the Company.

* *The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”*

”

PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR

On the same day, the Board resolved to propose to appoint Mr. Ma Yue (“**Mr. Ma**”) as a non-executive Director (the “**Proposed Appointment of Director**”).

The Proposed Appointment of Director was proposed by the nomination committee of the Board (the “**Nomination Committee**”) according to the nomination procedures for Directors of the Company and based on the needs of the Company and has submitted to the Board for review after considering the Director candidate’s relevant qualification by the Nomination Committee, and will then be submitted by the Board to the general meeting for final approval.

In accordance with the articles of association of the Company (the “**Articles of Association**”), the Proposed Appointment of Director is subject to the approval by the Shareholders at the general meeting of the Company.

Upon the approval of the Proposed Appointment of Director by the Shareholders, the Company will enter into a service contract with Mr. Ma, and Mr. Ma’s term of office as a Director shall commence from the date of his appointment by the general meeting and end on the expiration of the term of the current session of the Board. Pursuant to the Articles of Association, Mr. Ma will be subject to retirement by rotation and re-election upon the expiry of his term of office. The remuneration of Mr. Ma will be determined by the Board according to the authorization granted at the general meeting of the Company and in accordance with the Company’s remuneration standard regarding Directors implemented from time to time. According to the Company’s current remuneration standard, non-executive Directors will not receive any remuneration from the Company.

BIOGRAPHY OF MR. MA

Mr. Ma Yue, aged 43, obtained a master’s degree in science in microbiology from College of Life Sciences, Nankai University and a master’s degree in management in accounting from Chinese Academy of Fiscal Sciences. He is a senior economist and practicing pharmacist. Mr. Ma currently serves as the director of the operation management department (safety, environmental protection and quality management division) of China National Pharmaceutical Group Co., Ltd. (“**CNPGC**”). Mr. Ma joined CNPGC in October 2009 and has successively held various positions including the senior business supervisor of the international cooperation department, the assistant to the director of the international cooperation department, the deputy director of the office, the head of the operation management department and the director of the office (the office of the Party Committee and the

board office) of CNPGC. Mr. Ma has served as the director of the operation management department (safety, environmental protection and quality management division) of CNPGC since May 2025.

Save as disclosed above, as at the date of this announcement, Mr. Ma did not have any relationship with any Director, senior management or substantial or controlling Shareholder of the Company, or have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Mr. Ma did not hold any other positions in the Company or any of its subsidiaries, or any directorship in other listed companies in the last three years.

Save as disclosed above, the Company is not aware of any other matter that needs to be brought to the attention of the Shareholders or any matter in relation to the Proposed Appointment of Director that needs to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

A circular containing, among other things, details of the Proposed Appointment of Director will be despatched to the Shareholders of the Company in due course according to the manner in which the Shareholders have elected to receive corporate communications.

By order of the Board
Sinopharm Group Co. Ltd.
Zhao Bingxiang
Chairman

Shanghai, the PRC

9 June 2025

As at the date of this announcement, the executive Directors are Mr. Lian Wanyong and Mr. Sun Jinglin; the non-executive Directors are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Zu Jing, Mr. Xing Yonggang, Mr. Wen Deyong and Ms. Feng Rongli; and the independent non-executive Directors are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.